ArticleCurrent drug research reviews2026
Exploring Compound Kushen Injection's Anticancer Properties in Hepatocellular Carcinoma: An Integrated Approach of Network Pharmacology, Bioinformatics, and Experimental Validation.
Article in Current drug research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC), commonly referred to as primary liver cancer, is a malignant neoplasm that originates within the liver. Conventional treatment modalities frequently result in less than satisfactory outcomes, primarily attributed to the intricate physiological and pathological contexts. Compound Kushen Injection (CKI), formulated from the botanicals Sophora flavescens and Atractylodes macrocephala, is employed as a supplementary therapy in the treatment of advanced-stage malignant tumors, including HCC.
objectiveOur study combined network pharmacology, bioinformatics, GeneMANIA-based functional association (GMFA), and experimental validation to elucidate CKI's therapeutic targets and mechanisms.
methodsSTRING was used to build a protein-protein interaction network, and GO and KEGG analyses were performed with DAVID and ShinyGO on the overlapping targets of CKI and HCC. Hub targets were identified using CytoHubba and their clinical relevance was confirmed with GEPIA2. GMFA and TIMER assessed the functions of key hub genes. The findings were further verified through significant KEGG analysis, molecular docking, and experimental validation.
results10 hub targets were identified for CKI against HCC and analyzed for their impact on HCC patient survival and gene expression. GMFA confirmed four key hub genes, and TIMER assessed the correlation between SRC expression and immune infiltration. Significant KEGG analysis highlighted SRC's role in cell proliferation and migration through the MMP/EGFRPI3K/ AKT pathway. Molecular docking showed interactions between SRC and desmethylanhydroicaritin or resokaempferol. Experiments in HepG2 cells confirmed CKI's inhibitory effect on tumor cells.
conclusionCKI's anti-HCC effects may be exerted by regulating SRC via active compounds desmethylanhydroicaritin and resokaempferol.
Indexed as
Identifiers
40873363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.